Wakuu,
Wizara ya Afya nchini Kenya imeidhinisha kuanza kutumika kwa dawa ya kuzuia maambukizi ya VVU ijulikanayo kama lenacapavir, ambayo hutolewa mara mbili tu kwa mwaka.
Wizara imesema uamuzi huo umetokana na tathmini ya kina ya kisayansi kuhusu ubora, usalama na ufanisi wa dawa hiyo, iliyofanyika kwa kuzingatia sheria za Kenya pamoja na viwango vya kimataifa vya udhibiti wa dawa.
Akizungumza kuhusu hatua hiyo, Waziri wa Afya Aden Duale alisema kuwa mfumo wa muda mrefu wa lenacapavir unaorahisisha kutolewa mara mbili kwa mwaka ni mbadala muhimu kwa dawa za kumeza kila siku, hasa kwa watu wanaopata changamoto ya kutumia vidonge kila siku.
Duale amesema Kenya ni miongoni mwa nchi za kwanza barani Afrika kupendekeza lenacapavir kusajiliwa, hatua inayolingana na miongozo ya hivi karibuni ya afya ya umma duniani, ikiwemo mapendekezo ya Shirika la Afya Duniani.
Hatua hiyo inakuja wakati ambapo Kenya iliripoti ongezeko la asilimia 19 ya maambukizi mapya ya VVU mwezi Desemba 2025, huku idadi ya visa ikiongezeka kutoka 16,752 mwaka 2023 hadi 19,991 mwaka 2024, kulingana na taarifa ya Baraza la Taifa la Kudhibiti Magonjwa ya Syndemic.
=================================
The Ministry of Health has approved the rollout of lenacapavir, a twice-yearly HIV prevention drug.
The ministry says the recommendation follows a comprehensive scientific assessment of the quality, safety, and efficacy of lenacapavir, conducted in line with Kenyan law and applicable international regulatory standards.
โIts long-acting formulation allows it to be administered only twice a year, offering an important alternative to daily oral HIV prevention medicines. This is particularly beneficial for individuals who face challenges with taking pills every day,โ Health CS Aden Duale says.
Kenya is among the first African countries to recommend lenacapavir for registration, a decision that aligns with recent global public health guidance, including recommendations by the World Health Organization, Duale says.
He adds that the move reflects the countryโs growing regulatory capacity and leadership in enabling timely access to innovative health technologies of public health importance. Duale says the ministry will ensure the medicine is introduced in a timely, equitable and responsible manner for populations at substantial risk of HIV infection.
Source: Buzzroom Kenya